MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.leukres.2023.107308

Медицинская библиотека · Leukemia research · 2023

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.

Balsat Marie, Alcazer Vincent, Etienne Gabriel, Huguet Françoise, Berger Marc, Cayssials Emilie, Charbonnier Aude, Escoffre-Barbe Martine, Johnson-Ansah Hyacinthe, Legros Laurence, Roy Lydia, Delmer Alain, Ianotto Jean-Christophe, Orvain Corentin, Larosa Fabrice, Meunier Mathieu, Amé Shanti, Andreoli Annalisa, Cony-Makhoul Pascale, Morisset Stéphane, Tigaud Isabelle, Rea Delphine, Nicolini Franck Emmanuel

Наблюдательное исследованиеМногоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

Accelerated phase (AP) CML at onset and have poorer prognosis than CP-CML. We hypothesize that off-license use of second generation TKI (TKI2) as front-line therapy might counterbalance this poor prognosis, with limited toxicity. In "real-life" conditions, newly diagnosed patients meeting the ELN cytological criteria for AP-CML or harboring ACA and treated with first-line TKI2 were included in this retrospective multicenter observational study. We enrolled 69 patients [69.5 % male, median age 49.5 years, median follow-up 43.5 months], segregated into hematologic AP [HEM-AP (n = 32)] and cytogenetically defined AP [ACA-AP (n = 37)]. Hematologic parameters were worse in HEM-AP [spleen size (p = 0.014), PB basophils (p < .001), PB blasts (p < .001), PB blasts+promyelocytes (p < .001), low hemoglobin levels (p < .001)]. Dasatinib was initiated in 56 % patients in HEM-AP and in 27 % in ACA-AP, nilotinib in 44 % and 73 % respectively. Response and survival do not differ, regardless of the TKI2: 81 % vs 84.3 % patients achieved CHR, 88 % vs 84 % CCyR, 73 % vs 75 % MMR respectively. The estimated 5-year PFS 91.5 % (95%CI: 84.51-99.06 %) and 5-year OS 96.84 % (95%CI: 92.61-100 %). Only BM blasts (p < 0.001) and BM blasts+promyelocytes (p < 0.001) at diagnosis negatively influenced OS. TKI2 as front-line therapy in newly diagnosed AP-CML induce excellent responses and survival, and counterbalance the negative impact of advanced disease phase.

Для цитирования: Balsat Marie, Alcazer Vincent, Etienne Gabriel, Huguet Françoise, Berger Marc, Cayssials Emilie, Charbonnier Aude, Escoffre-Barbe Martine, Johnson-Ansah Hyacinthe, Legros Laurence, Roy Lydia, Delmer Alain, Ianotto Jean-Christophe, Orvain Corentin, Larosa Fabrice, Meunier Mathieu, Amé Shanti, Andreoli Annalisa, Cony-Makhoul Pascale, Morisset Stéphane, Tigaud Isabelle, Rea Delphine, Nicolini Franck Emmanuel. First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.. Leukemia research. 2023. DOI: 10.1016/j.leukres.2023.107308.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.